Protagonist Therapeutics (PTGX) PT Lowered to $13 at BMO Capital
BMO Capital analyst M. Ian Somaiya lowered his price target on Protagonist Therapeutics (NASDAQ: PTGX) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)